Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020142559 - INHIBITORS OF MENIN-MLL INTERACTION

Publication Number WO/2020/142559
Publication Date 09.07.2020
International Application No. PCT/US2019/069157
International Filing Date 31.12.2019
IPC
A61K 31/42 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
42Oxazoles
C07C 235/42 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
235Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
42having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
CPC
A61K 9/0014
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0014Skin, i.e. galenical aspects of topical compositions
A61K 9/0019
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
A61K 9/0031
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0031Rectum, anus
A61K 9/0048
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0048Eye, e.g. artificial tears
A61K 9/0053
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0053Mouth and digestive tract, i.e. intraoral and peroral administration
A61K 9/006
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0053Mouth and digestive tract, i.e. intraoral and peroral administration
006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
Applicants
  • BIOMEA FUSION, LLC [US]/[US]
Inventors
  • BUTLER, Thomas
  • PALMER, Jim
  • UPASANI, Ravi
  • WELSCH, Matthew
  • VEMPATI, Sridhar
  • KELLY, Brendan
  • PAINTER, Edward
Agents
  • PATHAK, Rahul
Priority Data
62/786,97431.12.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) INHIBITORS OF MENIN-MLL INTERACTION
(FR) INHIBITEURS DE L'INTERACTION MÉNINE-MLL
Abstract
(EN)
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
(FR)
L'invention concerne des composés hétérocycliques qui inhibent la liaison de la ménine et de MLL ou de protéines de fusion MLL. L'invention concerne également des inhibiteurs spécifiques de l'interaction ménine-MLL. L'invention concerne en outre des compositions pharmaceutiques qui comprennent ces composés. L'invention concerne par ailleurs des procédés d'utilisation de ces inhibiteurs de l'interaction ménine-MLL, seuls ou en combinaison avec d'autres agents thérapeutiques, pour le traitement de maladies ou de pathologies auto-immunes, de maladies ou de pathologies hétéro-immunes, du cancer, y compris du lymphome, de la leucémie et d'autres maladies ou pathologies dépendant de l'interaction ménine-MLL.
Latest bibliographic data on file with the International Bureau